Statin islands and PPAR ligands in platelets

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 5, 2009, Pages 620-621

  Phipps, Richard P ^a   Blumberg, Neil ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CD40 LIGAND; CHOLESTEROL; CLOPIDOGREL; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 8; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTAGLANDIN; PROTEIN KINASE C ALPHA; RETINOID X RECEPTOR; ROSIGLITAZONE; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; CLOFIBRIC ACID;

B LYMPHOCYTE; BLOOD TRANSFUSION; BLOOD VESSEL; CHOLESTEROL BLOOD LEVEL; CYTOKINE PRODUCTION; DENDRITIC CELL; DIABETES MELLITUS; DISEASE PREDISPOSITION; EDITORIAL; GRANULE CELL; HEART INFARCTION; HEMOSTASIS; HUMAN; IMMUNITY; INFLAMMATION; LEUKOCYTE; LOW DRUG DOSE; MACROPHAGE; MEGAKARYOCYTE; MITOCHONDRION; NEOPLASM; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; STROKE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; DRUG EFFECT; NOTE; PHYSIOLOGY;

ANTILIPEMIC AGENTS; BLOOD PLATELETS; CLOFIBRIC ACID; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 65549127778     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.184648     Document Type: Editorial

References (21)

1. Geddis AE, Kaushansky K. Immunology: the root of platelet production. Science. 2007;317:1689-1691.
2. McNicol A, Israels SJ. Beyond hemostasis: the role of platelets in inflammation, malignancy and infection. Cardiovasc Hematol Disord Drug Targets. 2008;8:99-117.
3. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594.
4. Phipps RP, Kaufman J, Blumberg N. Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion. Lancet. 2001;357: 2023-2024.
5. Prasad KS, Andre P, He M, Bao M, Manganello J, Phillips DR. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci U S A. 2003;100:12367-12371.
6. Kehry MR. CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. J Immunol. 1996;156:2345-2348.
7. van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells, and other cells. Curr Opin Immunol. 1997;9:330-337.
8. Khan SY, Kelher MR, Heal JM, Blumberg N, Boshkov LK, Phipps R, Gettings KF, McLaughlin NJ, Silliman CC. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood. 2006;108:2455-2462.
9. Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW, Phipps RP. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood. 2004;104:1361-1368.
10. Ray DM, Spinelli SL, Pollock SJ, Murant TI, O'Brien JJ, Blumberg N, Francis CW, Taubman MB, Phipps RP. Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles. Thromb Haemost. 2008;99:86-95.
11. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, Koenig W. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation. 2003;107:1954 -1957.
12. Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, Konrad T, Forst T. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005;45:1925-1931.
13. Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, Bishop-Bailey D, Warner TD, Mitchell JA. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. Faseb J. 2006;20: 326-328.
14. Ali FY, Armstrong PCJ, Dhanji AA, Tucker AT, Paul-Clark M, Mitchell JA, Warner TD. Anti-platelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol. 2009;29:706-711.
15. Rezaie-Majd A, Maca T, Bucek RA, Valent P, Muller MR, Husslein P, Kashanipour A, Minar E, Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002;22:1194-1199.
16. Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2008;5:542-553.
17. Paumelle R, Staels B. Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc Med. 2008;18:73-78.
18. Damas JK, Puccetti L, Aukrust P. Early anti-thrombotic and anti-inflammatory actions of statins and fibrates-time for adjuvant therapy in acute coronary syndromes? Thromb Haemost. 2005;94:1-3.
19. Barter PJ, Rye KA. Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? Circulation. 2006;113:1553-1555.
20. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168:2377-2381.
21. Kaufman J, Spinelli SL, Schultz E, Blumberg N, Phipps RP. Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion. J Thromb Haemost. 2007;5:788-796.